ERBB2 and neoplasm: Cetuximab prevents EGFR homo-dimerization/signaling, in contrast to trastuzumab which prevents hetero-dimerization of HER2 with other growth factors, leading to apoptosis of tumor cells in ovarian and breast malignancies [327,328,329].